Radioconjugates targeting CD33 in the treatment of cancers

Patent metadata

Field	Value
Publication number	US-12539340-B2
Application number	US-202217883434-A
Country	US
Kind code	B2
Filing date	Aug 8, 2022
Priority date	Aug 6, 2021
Publication date	Feb 3, 2026
Grant date	Feb 3, 2026

Abstract

The invention provides compositions and methods for treating cancers and proliferative disorders, including solid tumor cancers and non-myeloid hematological malignancies, using radioconjugates targeting CD33, alone or in combination with one or more radioconjugates targeting other cancer-associated targets such as DR5, 5T4, HER2, HER3, and TROP2, antibody drug conjugates targeting these or other cancer-associated targets, therapeutic antibodies targeting these or other cancer-associated targets, chemotherapy agents and regimens, and immune checkpoint inhibitors.

First claim

What is claimed is:

1 . A method for treating a solid tumor cancer or solid tumor premalignancy in a mammalian subject not afflicted with a myeloid-derived hematological cancer or myeloid-derived hematological premalignancy, comprising:
administering a therapeutically effective amount of a 225 Ac-labeled conjugate of p-SCN-Bn-DOTA and lintuzumab to the mammalian subject.

2 . The method of claim 1 , wherein the solid tumor cancer or solid tumor premalignancy comprises ovarian cancer, non-small cell lung carcinoma, head and neck squamous cell cancer, pancreatic cancer, renal cancer, breast cancer, metastatic breast cancer, tamoxifen-sensitive tamoxifen-resistant breast cancer, triple negative breast cancer, prostate cancer, castration-resistant prostate cancer (CRPC), pancreatic cancer, small cell lung carcinoma (SCLC), non-small cell lung carcinoma (NSCLC), hepatocellular carcinoma (HCC), cholangiocarcinoma, gastric cancer, colorectal cancer, esophageal cancer, or Barrett's esophagus.

3 . The method of claim 2 , wherein the mammalian subject is a human patient.

4 . The method of claim 3 , wherein the human patient is afflicted with a solid tumor cancer.

5 . The method of claim 1 , further comprising
administering at least one immune checkpoint inhibitor to the mammalian subject.

6 . The method of claim 5 , wherein the at least one immune checkpoint inhibitor comprises one or both of a PD-1 and PD-L1 inhibitor.

7 . The method of claim 6 , wherein the mammalian subject is a human patient.

8 . The method of claim 7 , wherein the human patient is afflicted with a solid tumor cancer.

9 . The method of claim 5 , wherein the at least one immune checkpoint inhibitor comprises a CTLA-4 inhibitor.

10 . The method of claim 9 , wherein the mammalian subject is a human patient.

11 . The method of claim 10 , wherein the human patient is afflicted with a solid tumor cancer.

12 . The method of claim 5 , wherein the mammalian subject is a human patient.

13 . The method of claim 12 , wherein the human patient is afflicted with a solid tumor cancer.

14 . The method of claim 1 , wherein the solid tumor cancer or solid tumor premalignancy is a CD33 low-expressing or CD33-negative solid tumor cancer or CD33 low-expressing or CD33-negative solid tumor premalignancy.

15 . The method of claim 14 , wherein the mammalian subject is a human patient.

16 . The method of claim 15 , wherein the human patient is afflicted with a solid tumor cancer.

17 . The method of claim 1 , wherein the mammalian subject is a human patient.

18 . The method of claim 17 , wherein the human patient is afflicted with a solid tumor cancer.

Assignees

• Actinium Pharmaceuticals Inc

Inventors

• Chen Mary M
• Desai Avinash
• Ludwig Dale L
• Berger Mark
• Seth Sandesh

Classifications

• A61P35/00 Primary

  Antineoplastic agents · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• A61K51/1027 Primary

  against receptors, cell-surface antigens or cell-surface determinants · CPC title

• C07K2317/90

  characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin · CPC title

• A61K2039/505

  comprising antibodies · CPC title